Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea · Delayed Price · Currency is KRW 4,190.00
-175.00 (-4.01%)
Sep 22, 2026, 3:30 PM KST
Vaxcell-Bio Therapeutics Market Cap
Vaxcell-Bio Therapeutics has a market cap or net worth of 97.45 billion as of September 22, 2026. Its market cap has decreased by -54.70% in one year.
Market Cap
97.45B
Enterprise Value
59.40B
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
4,190.00
ChartMarket Cap Chart
Since September 22, 2020, Vaxcell-Bio Therapeutics's market cap has decreased from 160.24B to 97.45B, a decrease of -39.19%. That is a compound annual growth rate of -7.95%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 22, 2026 | 97.45B | -58.06% |
| Dec 30, 2025 | 232.34B | -3.12% |
| Dec 30, 2024 | 239.82B | -53.54% |
| Dec 28, 2023 | 516.20B | -0.71% |
| Dec 29, 2022 | 519.87B | -21.31% |
| Dec 30, 2021 | 660.68B | -73.75% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 22, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| HLB Therapeutics | 177.16B |
| GC Genome | 163.19B |
| Anterogen.Co.,Ltd. | 151.49B |
| Helixmith | 138.14B |
| Genexine | 131.89B |
| MedPacto | 93.23B |
| iNtRON Biotechnology | 87.42B |
| Prestige BioPharma | 69.95B |